Простийпошук |
Розширенийпошук |
Покажчики
|
Професійний пошук |
Рубрикатор НБУВ |
Розподілений пошук |
Бази даних
Наукова періодика України - результати пошуку
Книжкові видання та компакт-дискиЖурнали та продовжувані виданняАвтореферати дисертаційРеферативна база данихНаукова періодика УкраїниТематичний навігаторАвторитетний файл імен осіб
 |
Для швидкої роботи та реалізації всіх функціональних можливостей пошукової системи використовуйте браузер "Mozilla Firefox" |
|
|
Повнотекстовий пошук
| Знайдено в інших БД: | Реферативна база даних (15) |
Список видань за алфавітом назв: Авторський покажчик Покажчик назв публікацій  |
Пошуковий запит: (<.>A=Shlyakhovenko V$<.>) | |||
|
Загальна кількість знайдених документів : 6 Представлено документи з 1 до 6 |
|||
| 1. | 
Janisch Yu. V. Glycopeptide vaccine on DNA-histone carrier and its impact on ?-potential of effector cells during experimental treatment of lymphoblastic leukemia [Електронний ресурс] / Yu. V. Janisch, A. B. Artamonova, V. A. Shlyakhovenko // Experimental oncology. - 2013. - Vol. 35, № 3. - С. 198-201. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2013_35_3_10 Aim - to increase the effectiveness of anticancer vaccine delivery and activity via its immobilization on reconstructed chromatin (RC). The hybrid mice of CDF-1 line with transplanted P-388 leukemia were used. Reconstructed chromatin was obtained from the thymus of inbred rats. Glycopeptide cancer vaccine prepared from P-388 leukemia cells, was immobilized of RC. Zeta-potential of tbyraocytes from tumor-bearing mice was calculated from Smoluchowski equation. The data have demonstrated the principal possibility of using the fragments of reconstructed chromatin of heterologous origin as a carrier of glycopeptide cancer vaccine prepared from the cells of P-388 leukemia. Preventive immunization with the correspondingly immobilized vaccine normalized zeta-potential of thymocytes in animals with transplanted P-388 leukemia. Conclusions: the use of immobilization of glycopeptide cancer vaccine on reconstructed chromatin improves anticancer activity of the vaccination. | ||
| 2. |
Ivanova T. S. Anticancer substances of mushroom origin [Електронний ресурс] / T. S. Ivanova, T. A. Krupodorova, V. Y. Barshteyn, A. B. Artamonova, V. A. Shlyakhovenko // Experimental oncology. - 2014. - Vol. 36, № 2. - С. 58-66. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2014_36_2_2 The present status of investigations about the anticancer activity which is inherent to medicinal mushrooms, as well as their bio-medical potential and future prospects are discussed. Mushroom products and extracts possess promising immimomodulating and anticancer effects, so the main biologically active substances of mushrooms responsible for immunomodulation and direct cytotoxicity toward cancer cell lines (including rarely mentioned groups of anticancer mushroom proteins), and the mechanisms of their antitumor action were analyzed. The existing to date clinical trials of mushroom substances are mentioned. Mushroom anticancer extracts, obtained by the different solvents, are outlined. Modern approaches of cancer treatment with implication of mushroom products, including DNA vaccinotherapy with mushroom immunomodulatory adjuvants, creation of prodrugs with mushroom lectins that can recognize glycocoqjugates on the cancer cell surface, development of nanovectors etc. are discussed. The future prospects of mushroom anticancer substances application, including chemical modification of polysaccharides and terpenoids, gene engineering of proteins, and implementation of vaccines are reviewed. | ||
| 3. |
Samoilenko О. А. Effect of polyamine metabolism inhibitors on Lewis lung carcinoma growth and metastasis [Електронний ресурс] / О. А. Samoilenko, O. A. Milinevska, O. V. Karnaushenko, V. A. Shlyakhovenko, S. P. Zaletok // Experimental oncology. - 2015. - Vol. 37, № 2. - С. 151-153. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_2_15 Aim - to study the influence of polyamine metabolism inhibitors on the growth, metastasis and ornithine decarboxylase (ODC) activity of Lewis lung carcinoma. Experiments were performed on female mice C57BI/6 with Lewis lung carcinoma. N omega-hydroxy-nor-arginine (nor-NOHA) and alpha-difluorometbylomithine (DFMO) were used as arginase and ODC inhibitors, correspondently. Inhibition of tumor growth was calculated by comparison of tumor volume in the treated and control groups. The average number of metastases per animal in the group and the average volume of pulmonary metastases per animal in the group have been determined. Determination of ODC - the key enzyme of the polyamine synthesis - in the samples of experimental tumors was performed by method of Luqman S. Administration of DFMO or it's combination with nor-NOHA resulted in the decrease of tumor growth rate, number and volume of lung metastases and was accompanied with reduced ODC activity in tumor tissue. Conclusion: modifiers of polyamine metabolism may be considered as promising targeted cancer therapy. | ||
| 4. |
Zaletok S. Green tea, red wine and lemon extracts reduce experimental tumor growth and cancer drug toxicity [Електронний ресурс] / S. Zaletok, L. Gulua, L. Wicker, V. Shlyakhovenko, S. Gogol, O. Orlovsky, O. Karnaushenko, A. Verbinenko, V. Milinevska, O., Todor I., Turmanidze T. Samoylenko // Experimental oncology. - 2015. - Vol. 37, № 4. - С. 262-271. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_4_7 Aim - to evaluate antitumor effect of plant polyphenol extracts from green tea, red wine lees and/or lemon peel alone and in combination with antitumor drugs on the growth of different transplanted tumors in experimental animals. Green tea extract (GTE) was prepared from green tea infusion. GTE-based composites of red wine (GTRW), lemon peel (GTRWL) and/or NanoGTE as well as corresponding nanocomposites were prepared. The total polyphenolics of the different GTE-based extracts ranged from 18,0 % to 21,3 %. The effects of GTE-based extracts were studied in sarcoma 180, Ehrlich carcinoma, B16 melanoma, Ca755 mammary carcinoma, P388 leukemia, L1210 leukemia, and Guerin carcinoma (original, cisplatin-resistant and doxorubicin-resistant variants). The extracts were administered as 0,1 % solution in drinking water (0,6 - 1,0 mg by total polyphenolics per mouse per day and 4,0 - 6,3 mg per rat per day). Tumor growth inhibition (TGI) in mice treated with NanoGTE, cisplatin or cisplatin + NanoGTE was 27 %, 55 % and 78 %, respectively, in Sarcoma 180 %, 21 %, 45 % and 59 %, respectively, in Ehrlich carcinoma; and 8 %, 13 % and 38 %, respectively in B16 melanoma. Composites of NanoGTE, red wine, and lemon peel (NanoGTRWL) enhanced the antitumor effects of cyclophosphamide in mice with Ca755 mammary carcinoma. The treatment with combination of NanoGTE were tested against cisplatin- or doxorubicin-resistant Guerin carcinoma. Moreover, the plant extracts lowered side toxicity of the drugs. Treatment with GTE, NanoGTE, and NanoGTRW decreased the levels of malondialdehyde in heart, kidney and liver tissue of experimental animals, as well as the levels of urea and creatinine in blood serum, increased erythrocyte and platelet counts, hemoglobin content, and decreased leucocyte counts. Conclusion: the obtained data indicate the prospects for further development of GTE and corresponding nanocomposites as auxiliary agents in cancer chemotherapy. | ||
| 5. |
Shlyakhovenko V. O. Ribonucleases. Possible new approach in cancer therapy [Електронний ресурс] / V. O. Shlyakhovenko // Experimental oncology. - 2016. - Vol. 38, № 1. - С. 2-8. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2016_38_1_2 In the review, the use of the ribonucleases for cancer therapy is discussed. Using of epigenetic mechanisms of regulation - blocking protein synthesis without affecting the DNA structure - is a promising direction in the therapy. The ribonucleases isolated from different sources, despite of similar mechanism of enzymatic reactions, have different biological effects. The use of enzymes isolated from new sources, particularly from plants and fungi, shows promising results. In this article we discuss the new approach for the use of enzymes resistant to inhibitors and ribozvmes, that is aimed at the destruction of the oncogene specific mRNA and the induction of apoptosis. | ||
| 6. | 
Shlyakhovenko V. O. NF-kB-p50-TFBS-complementary and c-myc-TFBS-complementary motifs in miRNAs involved in pathogenesis of different lympho- and myeloproliferative diseases [Електронний ресурс] / V. O. Shlyakhovenko, O. A. Orlovsky, O. A. Samoylenko // Клиническая онкология. - 2018. - Т. 8, № 1. - С. 18-23. - Режим доступу: http://nbuv.gov.ua/UJRN/klinonk_2018_8_1_4 В наших предшествующих исследованиях в со ставе премиРНК (stem-loop форм) человека, мыши и крысы выявлены различные типы мотивов, комплементарных сайтам связывания факторов транскрипции (ФТ) c-myc и NF-kB-p50. Также описаны различные типы информационной избыточности премиРНК относительно таких мотивов. Сформулирована гипотеза о том, что такие мотивы, будучи элементами деградома премиРНК, могут функционировать как альтернативные ФТ. Эта методология была применена для анализа характерных профилей экспрессии миРНК различных В-лимфопролиферативных и миелопролиферативных заболеваний. Выявлены следующие основные закономерности: значительная часть премиРНК, вовлеченных в патогенез различных гематологических заболеваний, содержит комплементарные мотивы ксайтам связывания ФТ c-myc и NF-kB-p50. Соответственно, элементы деградома таких премиРНК потенциально способны функционировать как альтернативные ФТ; каждой нозологической форме свойственен определенный характерный спектр ФТ-комплементарных мотивов в ее профиле экспрессии миРНК, что указывает на их реальное участие в механизмах дифференцировки клеток; различные типы информационной избыточности премиРНК соответствуют разным направлениям дифференцировки клеток. Полученные результаты дают основание также сформулировать следующие рекомендации для дифференциальной диагностики: гиперэкспрессия miR-320a и miR-323b в бластных клетках может быть весомым аргументом для диагностики хронической миелоцитарной лейкемии; гиперэкспрессия miRs 495 и 543 - сама по себе или, тем более, в сочетании с гипоэкспрессией miR-134, -542, -623, -671, -1182 - в бластных клетках может быть весомым аргументом для диагностики хронической миелоцитарной лейкемии; гипоэкспрессия miR-126 вбластных клетках может быть весомым аргументом для диагностики острой миелоцитарной лейкемии; гиперэкспрессия miR-185 и miR-324 в клетках лимфомы может быть весомым аргументом для диагностики лимфомы Беркитта; гиперэкспрессия miR-192a-2 в клетках лимфомы может быть весомым аргументом для диагностики мантийно-клеточной лимфомы. | ||
Попередній перегляд: 
Реферативна БД
 |
| Відділ інформаційно-комунікаційних технологій |
 Пам`ятка користувача |